QIAGEN Partners to Develop Novel Companion Diagnostic in Lung Cancer

Thursday, April 14, 2016 Cancer News J E 4
Collaboration with Mirati Therapeutics targets MET gene mutations to personalize treatment

HILDEN, Germany and GERMANTOWN, Maryland, April 13, 2016 /PRNewswire/ --

QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced a partnership with Mirati Therapeutics, Inc. (NASDAQ: MRTX) to co-develop and commercialize a companion diagnostic test to guide the use of Mirati's glesatinib (MGCD265), a targeted therapy under development for non-small cell lung cancer (NSCLC). The companies aim to create a regulator-approved test to personalize treatment decisions in NSCLC by detecting RNA biomarkers produced by exon 14 skipping mutations of the MET gene.

"We are pleased to partner with Mirati to commercialize a standardized companion diagnostic paired with glesatinib, a compound now in Phase II trials for NSCLC patients with cancer-driving MET alterations. Delivering insights on these clinically actionable variants holds potential to significantly improve clinical outcomes," said Peer M. Schatz, Chief Executive Officer of QIAGEN. "This companion diagnostic for glesatinib is the initial effort under a master collaboration agreement and we continue to discuss potential future projects across various sample types and platforms, such as PCR and NGS, to further expand targeted diagnostic capabilities in this arena."

Click here for full press release

Public Relations:

Dr. Thomas Theuringer Director Public Relations +49-2103-29-11826 Email:

Investor Relations:

John Gilardi Vice President Corporate Communications and Investor Relations +49-2103-29-11711 Email:




You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Ultrasound Headset May Be New Way to Recognize Con...
Innovative Medicines Canada statement on the House...